Heparin interferes with the uptake of liposomes in glioma

Publication date

2023-12-15

Authors

van Solinge, Thomas S
Friis, Kristina Pagh
O'Brien, Killian
Verschoor, Romy L
van Aarle, Jeroen
Koekman, ArnoldISNI 0000000394394014
Breakefield, Xandra O
Vader, PieterORCID 0000-0002-7059-8920ISNI 0000000396341338
Schiffelers, Raymond M.ORCID 0000-0002-1012-9815ISNI 0000000045237985
Broekman, Marike

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

In glioblastoma, a malignant primary brain tumor, liposomes have shown promise in pre-clinical and early phase clinical trials as delivery vehicles for therapeutics. However, external factors influencing cellular uptake of liposomes in glioma cells are poorly understood. Heparin and heparin analogues are commonly used in glioma patients to decrease the risk of thrombo-embolic events. Our results show that heparin inhibits pegylated liposome uptake by U87 glioma and GL261 cells in a dose dependent manner in vitro, and that heparin-mediated inhibition of uptake required presence of fetal bovine serum in the media. In a subcutaneous model of glioma , Cy5.5 labeled liposomes could be detected with in vivo imaging after direct intra-tumoral injection. Ex-vivo analysis with flow cytometry showed a decreased uptake of liposomes into tumor cells in mice treated systemically with heparin compared to those treated with vehicle only.

Keywords

Delivery, Glioblastoma, Glioma, Heparin, Liposomes, Uptake, Pharmaceutical Science

Citation

van Solinge, T S, Friis, K P, O'Brien, K, Verschoor, R L, van Aarle, J, Koekman, A, Breakefield, X O, Vader, P, Schiffelers, R & Broekman, M 2023, 'Heparin interferes with the uptake of liposomes in glioma', International journal of pharmaceutics X, vol. 6, 100191, pp. 1-8. https://doi.org/10.1016/j.ijpx.2023.100191